Advancing precision medicine in esophageal squamous cell carcinoma using patient-derived organoids

作者：Shitong Shen, Bing Liu, Wenyan Guan, Ziyao Liu, Yuqing Han, Yi Hu, Yiqiang Chen, Siyuan Liu, Jian He, Zhiwen Li, Weifeng Tang, Pengju Zhang, Wei Ren, Yudong Qiu, Hongping Zheng, Jingjing Li · 发表于：Journal of Translational Medicine · 年份：2024 · DOI：10.1186/s12967-024-05967-1 · 被引用次数：8 · 研究领域：Cancer Cells and Metastasis、Esophageal Cancer Research and Treatment、Single-cell and spatial transcriptomics

BACKGROUND: Patient-derived organoids (PDOs) represent a promising approach for replicating the characteristics of original tumors and facilitating drug testing for personalized treatments across diverse cancer types. However, clinical evidence regarding their application to esophageal cancer remains limited. This study aims to evaluate the efficacy of implementing PDOs in clinical practice to benefit patients with esophageal squamous cell carcinoma (ESCC). METHODS: Fresh surgical biopsies were obtained from patients with esophageal cancer for the establishment of PDOs. These PDOs were subsequently characterized through histological analysis. A customized drug panel, based on standard-of-care chemotherapy regimens, was applied to the PDOs. The resulting drug sensitivity profiles were then correlated with the clinical responses observed in individual patients undergoing actual treatment. RESULTS: A total of 34 PDOs were successfully established with a 61.8% success rate. The classification method based on chemotherapy sensitivity closely corresponded to clinical responses. The paclitaxel plus cisplatin (TP)-sensitive group demonstrated significantly longer progression-free survival (PFS) compared to the resistant groups, Hazard ratio (HR), 5.12; 95% confidence intervals (CI 0.58-44.71; p < 0.05), thus illustrating the potential of this approach for guiding personalized treatment strategies. CONCLUSION: Organoid biobanks were established across multiple institutes to facilitate...